Most CML patients express either e13a2 or e14a2 BCR-ABL1 fusion transcripts but approximately 5% of patients express variant transcripts that may involve fusion of alternative exons, insertions, or breakpoints within exons. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.